Targeting a specific signaling pathway to treat high-risk osteosarcoma
Official title: Identifying and overcoming mechanisms of resistance to effectively target the TBL1/β-catenin signaling axis for high-risk osteosarcoma
Funded at Emory University · NIH-10943147 · Data updated 2026-11-12
This study is looking at a new way to help people with high-risk osteosarcoma, a tough type of bone cancer, by testing a special medicine called Tegavivint that aims to stop the cancer from growing and spreading while keeping healthy cells safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | August 12, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $376,982 |
| NIH project number | 1R01CA292466-01 |
| Project ID | NIH-10943147 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pediatric patients diagnosed with high-risk osteosarcoma, particularly those who have relapsed or are refractory to standard treatments.
✕Less likely to help
Patients with low-risk osteosarcoma or those whose cancer has not progressed may not receive benefit from this research.
What this research studies
This research focuses on understanding and overcoming the mechanisms that make high-risk osteosarcoma resistant to treatment. It investigates the role of the TBL1/β-catenin signaling axis, which is involved in tumor growth and spread. The study utilizes a novel small molecule inhibitor called Tegavivint, which aims to disrupt the harmful interactions within this signaling pathway without affecting normal cell functions. By doing so, the research seeks to improve treatment outcomes for patients with this aggressive form of bone cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for high-risk osteosarcoma, potentially improving survival rates and quality of life for affected patients.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting the Wnt signaling pathway in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Yustein, Jason — Emory University
- Study coordinator: Yustein, Jason
Related research
Other NIH-funded projects on the same topics.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Histotripsy + immune boost to fight osteosarcoma
A new treatment idea combines a precise non-surgical ultrasound method with an immune-boosting compound to help fight bone cancer in people and dogs.
-
Genomically guided drug testing for osteosarcoma in patient-derived models
A precision approach tests new drugs on osteosarcoma models created from patients to find promising treatments for kids and teens.
-
New ways to stop osteosarcoma from spreading
Researchers are testing new approaches to block how osteosarcoma spreads, with the aim of improving survival for children and adults with metastatic disease.
-
Targeting OST Redundancy to Treat Osteosarcoma
A study in people with advanced bone cancer to see if new OST-targeting drugs can slow or stop tumor growth.
-
Focal Adhesion Kinase inhibitor to block osteosarcoma spread to the lungs
A cancer treatment plan tests whether blocking a specific cell signal can stop osteosarcoma from growing and spreading to the lungs in kids and young people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.